A new publication involving cerebrolysin was released on August 17, 2026. The paper, titled "Post-Endovascular Thrombectomy Perfusion Imaging (CT and MR) as a Prognostic Biomarker and Patient-Selection Tool for Adjuvant Therapy: A Systematic Review, Meta-Analysis, and Clinical Threshold Framework," appeared in the Journal of Stroke and Cerebrovascular Diseases, the official journal of the National Stroke Association.
The publication is described as a systematic review, meta-analysis, and clinical threshold framework. It focuses on perfusion imaging methods, including CT and MR, used after endovascular thrombectomy. According to the title, the work examines these imaging approaches as tools for prognosis and for selecting patients who may receive adjuvant therapy.
No results, conclusions, or efficacy data from this publication have been provided beyond the title and journal listing. Cerebrolysin remains classified as an unapproved research compound, and this listing does not indicate any change to that regulatory status. Readers should not interpret this publication announcement as confirmation of any clinical outcome or therapeutic benefit.
Those interested in learning more about this publication can consult the source link provided. For general background on cerebrolysin, readers can refer to the compound overview available on this platform.